These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 1778870)

  • 1. Selection and characterization of cefepime-resistant gram-negative bacteria.
    Piddock LJ; Griggs DJ
    J Antimicrob Chemother; 1991 Nov; 28(5):669-76. PubMed ID: 1778870
    [TBL] [Abstract][Full Text] [Related]  

  • 2. beta-Lactamase expression and outer membrane protein changes in cefpirome-resistant and ceftazidime-resistant gram-negative bacteria.
    Piddock LJ; Traynor EA
    J Antimicrob Chemother; 1991 Aug; 28(2):209-19. PubMed ID: 1778852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of the mechanisms of decreased susceptibility of aztreonam-resistant and ceftazidime-resistant Enterobacteriaceae.
    Piddock LJ; Traynor EA; Wise R
    J Antimicrob Chemother; 1990 Dec; 26(6):749-62. PubMed ID: 2081717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of FCE 22101-resistant Enterobacteriaceae and the effect of FCE 22101 upon the activity of anti-pseudomonal beta-lactams for Pseudomonas aeruginosa.
    Piddock LJ; Traynor EA
    J Antimicrob Chemother; 1991 Sep; 28(3):369-75. PubMed ID: 1960118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inducible type I beta-lactamases of gram-negative bacteria and resistance to beta-lactam antibiotics.
    Curtis NA; Eisenstadt RL; Rudd C; White AJ
    J Antimicrob Chemother; 1986 Jan; 17(1):51-61. PubMed ID: 3485092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activity of cefepime against ceftazidime- and cefotaxime-resistant gram-negative bacteria and its relationship to beta-lactamase levels.
    Fung-Tomc J; Dougherty TJ; DeOrio FJ; Simich-Jacobson V; Kessler RE
    Antimicrob Agents Chemother; 1989 Apr; 33(4):498-502. PubMed ID: 2499250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of cefepime against ceftazidime-resistant gram-negative bacilli using low and high inocula.
    Johnson CC; Livornese L; Gold MJ; Pitsakis PG; Taylor S; Levison ME
    J Antimicrob Chemother; 1995 Jun; 35(6):765-73. PubMed ID: 7559188
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Post-marketing surveillance of antibacterial activities of cefozopran against various clinical isolates--II. Gram-negative bacteria].
    Igari J; Oguri T; Hiramatsu N; Akiyama K; Koyama T
    Jpn J Antibiot; 2003 Oct; 56(5):458-96. PubMed ID: 14692381
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resistance to third-generation cephalosporins in Barbados.
    Levett PN; Holt HA; McGowan AP
    West Indian Med J; 1993 Jun; 42(2):69-71. PubMed ID: 8367967
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of ampC derepression on cefepime MIC in Enterobacterales with chromosomally encoded inducible AmpC β-lactamase.
    Kohlmann R; Bähr T; Gatermann SG
    Clin Microbiol Infect; 2019 Sep; 25(9):1158.e1-1158.e4. PubMed ID: 31128286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Post-marketing surveillance of antibacterial activities of cefozopran against various clinical isolates--II. Gram-negative bacteria].
    Igari J; Oguri T; Hiramatsu N; Akiyama K; Koyama T
    Jpn J Antibiot; 2002 Feb; 55(1):22-60. PubMed ID: 11977920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro antibacterial activities of FK037: a new parenteral cephalosporin.
    Inoue K; Inoue E; Mitsuhashi S
    Chemotherapy; 1995; 41(4):257-66. PubMed ID: 7555206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity of cefpirome against beta-lactamase-inducible and stably derepressed Enterobacteriaceae.
    Binfiglio G; Stefani S; Nicoletti G
    Chemotherapy; 1994; 40(5):311-6. PubMed ID: 7956454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo selection of Enterobacter aerogenes with reduced susceptibility to cefepime and carbapenems associated with decreased expression of a 40 kDa outer membrane protein and hyperproduction of AmpC beta-lactamase.
    Fernández-Cuenca F; Rodríguez-Martínez JM; Martínez-Martínez L; Pascual A
    Int J Antimicrob Agents; 2006 Jun; 27(6):549-52. PubMed ID: 16697150
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modification of the susceptibility of gram-negative rods producing ESβLS to β-lactams by the efflux phenomenon.
    Laudy AE; Osińska P; Namysłowska A; Zając O; Tyski S
    PLoS One; 2015; 10(3):e0119997. PubMed ID: 25793625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activity of avibactam (NXL104) in combination with β-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniae.
    Aktaş Z; Kayacan C; Oncul O
    Int J Antimicrob Agents; 2012 Jan; 39(1):86-9. PubMed ID: 22041508
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [In vitro activity of cefepime against ESBL-positive clinical strains of gram-negative rods].
    Rokosz A; Sawicka-Grzelak A; Luczak M
    Med Dosw Mikrobiol; 2005; 57(4):409-16. PubMed ID: 16773834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extension of resistance to cefepime and cefpirome associated to a six amino acid deletion in the H-10 helix of the cephalosporinase of an Enterobacter cloacae clinical isolate.
    Barnaud G; Labia R; Raskine L; Sanson-Le Pors MJ; Philippon A; Arlet G
    FEMS Microbiol Lett; 2001 Feb; 195(2):185-90. PubMed ID: 11179650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Yearly changes in antibacterial activities of cefozopran against various clinical isolates between 1996 and 2001--II. Gram-negative bacteria].
    Suzuki Y; Nishinari C; Endo H; Hiramatsu N; Akiyama K; Koyama T
    Jpn J Antibiot; 2003 Aug; 56(4):309-35. PubMed ID: 14567255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Yearly changes in antibacterial activities of cefozopran against various clinical isolates between 1996 and 2000--II. Gram-negative bacteria].
    Suzuki Y; Nishinari C; Endo H; Tamura C; Jinbo K; Hiramatsu N; Akiyama K; Koyama T
    Jpn J Antibiot; 2002 Apr; 55(2):154-80. PubMed ID: 12071094
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.